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Summary
Objectives To determine the views of patients and members of the
public about who should pay for expensive new cancer drugs not
recommended by the National Institute for Health and Clinical Excellence
(NICE).
Design A study-specific questionnaire was used to elicit the views of
patients and the general public between April and June 2010. It examined
whether participants thought patients should be told about all possible
cancer treatments, if the NHS should always fund non-NICE
recommended drugs and attitudes towards self-funding/co-payments.
The influence of sociodemographic factors on responses was also
examined.
Setting Oncology clinics in Sussex and various locations including old
persons’ lunch clubs, parks, sports venues and support groups.
Participants Two hundred and 10 patients with common solid
tumours, and 416 members of the general public
Main outcome measures Frequencies of responses to items
regarding payments for expensive anti-cancer drugs stratified by
sociodemographic factors and comparison of responses between patients
and members of the public.
Results Most respondents (70% [147/210] of patients and 64% [266/
416] of the general public) had heard of NICE. Both groups believed that
doctors should tell patients about all available cancer treatments even if
the NHS cannot pay (94%, 196/208; 93%, 388/415). However, only 49%
(101/207) of patients and 36% (146/409) of the public believed that the
NHS should always fund all new cancer drugs that have failed health
technology assessments. Strong predictors of willingness to purchase
expensive new cancer drugs included younger age (<45 years), sex
(female) and higher educational level.
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Conclusion The general population appear realistic about the
difficulties of providing funding for expensive new drugs. A
communication skills training course has been developed to help
clinicians with these difficult consultations.
Introduction
Costs of novel cancer drugs are escalating world-
wide creating a multitude of economic, social
and ethical dilemmas for healthcare providers
and commissioners as well as patients and their
relatives. It is not always easy to balance the indi-
vidual desires of patients for costly new treat-
ments that might be clinically appropriate, with
wider societal obligations and responsibilities of
ensuring some equity when dividing up a finite
budget. It is extremely hard, if not unreasonable,
to expect a dying patient to consider which
elements of healthcare they would see deprived
of resources to enable them to have unrestricted
access to cancer drugs, especially those that have
failed health technology assessments (HTAs).
Many doctors find discussions about individ-
ual/exceptional funding requests and self-
funding extremely difficult so fail to inform
patients about the availability of some of the
newer treatments that have not received positive
recommendations. Patients need to be given infor-
mation to make decisions that are right for them
and oncologists are often poor judges of the
general information needs of their patients.1
Cancer charities said that patients were being
‘left in the dark’ about putatively life-extending
drugs not routinely available in the NHS2 and fail-
ures to discuss novel treatments is paternalistic.
There are few data showing what the views of
the general public or patients in the UK are
towards paying for expensive new anti-cancer
drugs. Surveys elsewhere show that patients
want information about high-cost drugs even if
they cannot afford them. Members of the Breast
Cancer Network in Australia were interviewed
to examine their knowledge, as well as experi-
ences and attitudes towards drugs costing
>A$900 per week.3 One finding was a difference
as to what was deemed as high cost; a majority
thought >A$100 per week high, with 57% of
women considering A$50 per week high,
(although the duration of treatment influenced
these views). Over one-quarter (28%) had dis-
cussed high-cost drugs with their oncologist and
none had declined treatment due to financial con-
straints. In an earlier survey of the Australian
public similar responses were found, with 91%
of people wanting to be told about expensive
drugs that could improve survival by an
additional 4–6 months, and 51% prepared to pay
for them.4
In the UK, the Richards Report5 clarified the
procedures that would permit additional self-
payments by patients, and thus ensure that they
would not lose entitlement to other National
Health Service (NHS) treatment. The report also
advised that doctors should receive communi-
cation skills training to assist consultations about
this difficult topic. We conducted two surveys:
one of doctors’ experiences discussing additional
payments since publication of the Richard’s
Report6 and another, reported here, of patients
and the general public’s views of expensive
cancer drugs and their willingness to pay for
them.
Participants and methods
Questionnaire
An 18-item study-specific questionnaire devised
by the authors with lay input examined issues
including: awareness of the National Institute for
Health and Clinical Excellence (NICE); desires
for information about drugs not funded by the
National Health Service (NHS); and willingness
to pay for cancer drugs either for themselves or
for relatives. Attitudes and willingness to self-
fund were examined further through hypothetical
scenarios about likely therapeutic gains including
extension of life, quality of life, numbers of
patients likely to benefit, and the financial costs.
We also explored the influence that age, education
and the type of newspaper read had on partici-
pants’ responses; comments to explain their
choice of response were encouraged.
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Participants
Patients
Aconvenience sample of 220 patientswith common
solid tumours, attending for routine follow-up
appointments at oncology clinics in Sussex read
an information sheet about the survey. Consenting
patients completed questionnaires in clinic or at
home to return by post. The patient study had
ethical approval from the Surrey Research Ethics
Committee (Ref: 10/H1109/20).
Public
A convenience sample of 610 members of the
general public was approached in various
locations including the seafront, parks, trains, uni-
versity campus, old persons’ lunch-clubs, sports
venues and a support group for young mothers,
enabling a broad sociodemographic mix of
people. The public survey had ethical consent
from the Brighton & Sussex Medical School (10/
019/JEN) and the study was sponsored by the
Brighton & Sussex Medical School.
Statistics
We conducted a descriptive analysis of the survey
data comparing frequencies of responses between
patients and the public. These comparisons were
formalized through logistic regressions for binary
variables indicating whether participants were
aware ofNICE,wouldwant to be told about expens-
ive new drugs andwhether theNHS should pay for
them. Similarly, logistic regression models were
fitted for binary variables indicating willingness to
pay for drugs offering an extension of life and for
improving quality of life for themselves or a close
relative, omitting ‘unsure’ responses. The odds
ratio associated with a group indicator, for example
public, measures the relative size of the odds of a
positive response formembers of the public in com-
parison with the odds for those in the group of
patients. In all our models, we adjusted for the
demographic characteristics described in Table 1
and the type of newspaper people read. The covari-
ates age and level of education were re-coded using
the first three empirical quartiles as cut-off points.
Type of newspaper read was coded into three cat-
egories: ‘I don’t read newspapers’; ‘broad sheet’;
and ‘red top’. Goodness of fit was assessed using
the deviance of fitted logistic regression models.
Results
The socioeducational demographics of respon-
dents are shown in Table 1.More of the public were
younger, with higher educational qualifications
and had private health insurance (P< 0.001).
Responses to survey questions are shown in
Table 2.
NICE and the influence of newspapers
Most patients (70%; 147/210) had heard of NICE
compared with 64% (266/416) of the public.
Members of the public affected by cancer them-
selves were also more likely to have heard of
NICE (OR= 2.87, P= 0.009). Forty-one percent
(169/414) of the public and 30% (62/210) of
patients did not read newspapers. Those who
read broadsheet newspapers in both groups were
more likely to be aware of NICE than those
never reading newspapers; this effect remained
when educational level was taken into account
(OR= 1.70, P= 0.024).
Non-NHS funded drugs
The overall majority did not think that the NHS
should pay for all new cancer drugs, however
more patients (49% (101/207) than the general
public 36% (146/409) felt that the NHS should
‘always’ pay (OR= 1.61, P= 0.009). Those with
higher educational qualifications in both groups
were less likely to agree that the NHS should do
so (OR= 0.54, P= 0.002).
Over one-quarter of patients (27%, 56/207) and
one-third of the public (33%, 136/409) thought
payment should only occur if NICE recommended
the drug. In both groups, those who read broad
sheets were less likely to agree that the NHS
should always pay compared to those who do
not read newspapers (OR= 0.58, P= 0.01). Some
examples of comments around this include:
‘The NHS gives a fantastic service to cancer
patients; however they have to work to a budget, in
order for everyone to have some form of treatment.’
(Patient 101)
‘Rely on NICE rather than press as to whether the
NHS should pay for the drugs.’ (Public 505)
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Should doctors tell patients about all
available cancer treatments?
Both groups strongly believed doctors should
discuss all treatments even if the NHS does not
pay for them (94% of patients [196/208]; 93% of
public [388/415]). Some recognized the difficulties
that doctors faced when discussing expensive new
cancer treatments:
‘All drugs should be priced to give all people the
same chance of getting better. What a horrid situ-
ation for doctors to know of a drug that could help
a person and that he has to tell you about it,
knowing that it is very expensive and you would
have to make the choice, think about the family
and how this affects them as well.’ (Patient 70)
Other comments revealed that if doctors did not
discuss the topic then patients might access more
unreliable sources.
‘A difficult subject, but I would want all information
available to make an informed decision. I (and others
I’m sure) obtain information from the Internet
anyway but getting full information from a reliable
health professional is important.’ (Patient 97)
Some, as the following quote shows, did not think
that doctors should have to discuss funding.
‘Doctors should not have to worry about the finance.
If a drug is recommended an administrator should
discuss with the patient why NICE won’t fund it;
this would enable the doctor to get on with his/her
job and the administration get involved and under-
stand the implications and effect on lack of/or incon-
sistent funding.’ (Patient 40)
Willingness to pay in extension of life or
quality of life (QoL) scenarios
Patients and the public were asked to consider
whether or not, if their cancer was getting worse,
they would want their doctor to discuss self-
funding options for a drug that might lengthen
life by an extra 4–5 months. Most patients and
the public were strongly in favour of such discus-
sions (84% [175/208] and 82% [339/414], respect-
ively). However when told that the drug might
benefit only two out of five patients, that there
was no way of knowing who might benefit and
it would cost £4000 a month, more of the public
(22% [93/414]) were willing to pay compared
with patients (15% [30/206]). The numbers
willing to consider payment when told that the
drug might improve the QoL, by reducing
Table 1
Demographics of patients and public
Patients
n= 210
Public
n= 417
Sex
Male 89 (42%) 185 (44%)
Female 119 (57%) 232 (56%)
Missing 2 (1)
Age group (years)
18–25 2 (1%) 25 (6%)
26–35 5 (2%) 53 (13%)
36–45 11 (5%) 71 (17%)
46–55 33 (16%) 79 (19%)
56–65 41 (20%) 76 (18%)
>65 117 (56%) 113 (27%)
Missing 1
Partner
Yes 143 (68%) 270 (65%)
Missing 2 (1%) 1 (0%)
Education qualifications
None 74 (35%) 71 (17%)
GCSE 49 (23%) 88 (21%)
A levels 16 (8%) 49 (12%)
College/Degree/Diploma 68 (32%) 203 (49%)
Missing 3 (1%) 6 (1%)
Private health insurance
Yes 17 (8%) 86 (21%)
No 188 (90%) 328 (79%)
Missing 5 (2%) 3 (1%)
Cancer site 
Breast 75 (36%)
Colorectal 25 (12%)
Urological 47 (22%)
Other 63 (30%)
Time since diagnosis (years)
<1 56 (27%)
1–3 76 (36%)
4–5 43 (20%)
>5 35 (17%)
Type of treatment
Surgery 103 (49%)
Radiotherapy 113 (54%)
Chemotherapy 120 (57%)
Hormone 58 (28%)
45 had cancer; 13 still treated; 65% had a familymember with cancer
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symptoms such as pain or feeling tired, increased
for the public to 30% (123/416) and to 16% (32/
206) for patients. The varying attitudes are
reflected in some of the quotes below:
‘Having had cancer myself (twice) I do not feel that
£4000 per month can be justified when there are
people with a much greater need on the NHS.’
(Patient 36)
‘If we are talking about drugs that will only lengthen
life by 4–5 months then £4000 is a lot of money! The
NHS does not have unlimited funds and doctors
have limited time in a consultation. There is no
point telling a patient about a drug the NHS
cannot provide.’ (Patient 26)
‘Quality of life is critically important. If survival
can be prolonged with high QOL, I would feel
much more positive than if life is prolonged with
poor QOL.’ (Public 202)
How would you pay for the drugs?
Patients were asked if they would: pay for the
drug from personal funds; ask family or friends;
or re-mortgage the house. More indicated that
they would re-mortgage the house (22%, 44/201)
or use personal funds (20%, 40/203) than ask
family or friends (9%, 18/201). Members of the
public were more likely to pay for the drug for
themselves out of personal funds (31%, 128/413),
with 30% (121/410) considering re-mortgaging
the house and only (15%, 60/410) prepared to
ask family members or friends. Differences
between patients and the public were not statisti-
cally significant when age and educational level
were taken into account, however if members of
the public actually, rather than hypothetically,
had a close family member with cancer then
they were more likely to be willing to re-mortgage
the house to pay for treatment (OR= 1.73, P=
0.042). In both groups, women (49%, 99/204)
were significantly more likely to pay for unfunded
treatments that might improve their own quality of
life than were men (30%, 56/187), when omitting
unsure answers (OR= 2.25; P= 0.001).
When ‘unsure’ answers were excluded, age
also influenced responses to several questions:
people older than 65 years were significantly less
likely to want to pay for treatment, compared to
those between 18 and 45 years old (P< 0.001).
‘I’m an 80-year-old pensioner, paid taxes all my life.
Don’t expect to pay for my treatment.’ (Patient 199)
‘I am an OAP living off no income. I couldn’t afford
to pay any money so if they stop the treatment I’m
afraid that would be it. Sorry.’ (Patient 100)
‘Certainly in my situation at age of 40 with two
young children, I would find the money from some-
where if it meant that my life was prolonged or made
easier. We should be given the opportunity if there
are better drugs out there.’ (Patient 89)
‘I am 28 years old: too young to give up and I would
fight for anything that may give me a chance to
survive longer.’ (Patient 65)
Preparedness to pay for relatives
When the public were asked to consider the scen-
ario of paying for a close relative responses
showed a more positive inclination than if it was
for themselves, with 35% (145/416) saying they
would pay if it lengthened life and 43% (178/
416), if it improved their relative’s quality of life.
When the ‘unsure’ responses are excluded, 11%
(21/183) members of the public would pay to
lengthen their relative’s life but not their own,
compared with only 2% (4/183) who would pay
for themselves but not their relative (P< 0.001).
Similarly 13% (27/209) would pay to improve
their relative’s QoL compared with their own
(2%, 4/209; P< 0.001). This is reflected in the
following quotes:
‘£4000 is a lot of money to find, but if it was for a
very close family member (e.g. husband, child,
grandchild), it might be a possibility to raise the
money. Re-mortgage the house for instance.’
(Public 597)
‘My father died eight years ago from cancer and I
would have wanted to give anything a try.’
(Public 10)
Women (77%, 110/143) were more likely to pay if it
improved their relative’s quality of life compared
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to men (58%, 68/119), omitting unsure answers
(OR= 2.54, P= 0.002). Similarly 68% (86/127)
women compared with 50% of men (59/118)
would also be more likely to pay if it lengthened
life, excluding unsure answers (OR= 2.08, P=
0.012).
Age was an important factor for all the ques-
tions concerning paying for a close relative.
Older people (>65 years) were less likely to pay
compared with younger age groups (18–45
years) (P ≤0.002). The odds ratios comparing the
responses of oldest and youngest age groups,
ignoring ‘unsure’ answers were: from personal
funds (OR= 0.25, P= 0.001); re-mortgaging
house (OR= 0.24, P< 0.001); ask the family or
friends (OR= 0.121; P< 0.001); lengthen life for
only two out of five people (OR= 0.27, P=
0.002) and improve QoL (OR= 0.26, P= 0.001).
Discussion
The results from the survey show that the majority
of patients and the general public are more san-
guine about the stark reality that not all cancer
drugs can and should be funded by the NHS
with its finite resources. One-third of the public
and more than one-quarter of patients felt that
only those drugs that NICE recommend as worth
the costs should be funded. Importantly the
majority of both groups did wish to be informed
about all possible cancer treatment options, even
those not paid for by the NHS.
This survey was conducted in a relatively afflu-
ent part of the UK (South East England) as
reflected in the 21% who had private health insur-
ance, compared to the national figure in 1998–
1999 of 18% for a household headed by a pro-
fessional group or 8% of households with a
retired household head.7 We did not collect indi-
viduals’ household income data, nor explore the
price ranges that might encourage people to con-
sider self-funding drugs, but the results mirror
findings from two Australian surveys.3,4
In our study, groups strongly favoured disclos-
ure about unsubsidized expensive anti-cancer
drugs and wanted to be active participants in
treatment decision-making, as did 91% of the
public in the Australian survey.4 Age was a
strong predictor of the public’s desire to be
treated with the expensive cancer drug, with
86% of those under 70 years wanting to receive
treatment compared with 73% of those aged 70
years or older. Also, older patients were less
likely to want to pay or ask relatives to pay for
the drug, whether it gave extra length of life or
improved quality of life. The results show a
range of responses to the vexed topic as to who
should pay for expensive new cancer drugs that
fail to achieve reasonable thresholds following
health technology assessment. So how do clini-
cians in the UK deal with this situation?
There are few data collected about patients and
the general public’s views about non-NHS-funded
anti-cancer drugs. Oncologists find discussions
about the subject challenging; they worry about
distressing patients and their families by offering
a treatment that the NHS cannot fund and which
patients may not be able to afford.8 In a recent
UK study, many clinicians felt very uncomfortable
about even raising the issue of unfunded drugs
especially if they worked solely within the NHS.6
Additionally, the overwhelming majority of clini-
cians (98%) had received no help or guidance in
having such discussions. The difficulty talking
about additional payments for expensive new treat-
ments is not limited to Australia and the UK. A
recent article comparing the attitudes of Canadian
and US members of ASCO, stated that 26% of the
167 respondents rarely or never discussed costs
with patients and 31% acknowledged a high
degree of discomfort when doing so.9
Since the survey reported here was con-
ducted, the UK Coalition Government
announced that they would end the power of
NICE to make recommendations about which
drugs the NHS should fund. In response to the
complaints by some cancer charities, doctors
and newspaper campaigns, they have also estab-
lished a £200 million ‘Cancer Drugs Fund’ which
is administered by independent panels in differ-
ent Strategic Health Authorities.10 The interim
£50 million fund covering six months from
October 2010–March 2011 proved difficult to
deliver with fewer applications than expected.11
Even when the system is operational, discus-
sions about access to expensive new drugs
through individual/exceptional funding
requests, the cancer fund and/or additional self-
payments by patients will have to continue.
Helping clinicians deliver these uncomfortable
discussions with patients in an appropriate and
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balanced manner is vital to enable wise decision-
making. One recommendation in the Richards
Report5 was for the Department of Health to
commission a training programme to help all
parties. An educational DVD package entitled
‘Getting the Right Balance’ has recently been
completed with seven different scenarios depict-
ing some of the issues and difficulties that arose
from our surveys of both clinicians, patients and
the public.
Conclusion
Despite desires to avoid a ‘post-code lottery’,
policy changes have created some continued con-
fusions about the process for accessing funds This
together with stark economic realities means that
additional payments are likely to stay for some
time to come. Doctors, patients and their families
will therefore need to engage in difficult discus-
sions about the true cost-benefits of further treat-
ments at a time when they are just coming to
terms with the seriousness of their illness.
However, the patients and the general public
who participated in this survey appear under-
standing, sanguine and realistic about the
problem of funding expensive new drugs than
perhaps even the policymakers may realize.
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